Empowering treatment: insights from 35 months follow-up highlight the benefits of cemiplimab monotherapy and continued immunotherapy plus chemotherapy beyond progression in advanced non-small cell lung cancer patients with high PD-L1 expression
Empowering treatment: insights from 35 months follow-up highlight the benefits of cemiplimab monotherapy and continued immunotherapy plus chemotherapy beyond progression in advanced non-small cell lung cancer patients with high PD-L1 expression
Authors
- A. Barba Joaquín (ORCID: https://orcid.org/0000-0003-2500-0253)
- M. Majem Tarruella
- Maria Alba Sorolla (ORCID: https://orcid.org/0000-0002-2180-0408)
- Sergio Martínez-Recio (ORCID: https://orcid.org/0000-0001-8056-7100)
- M. Portu Grive
Publication Details
- Journal
- AME Clinical Trials Review
- Published
- 2025-03-24
- DOI
- https://doi.org/10.21037/actr-24-107
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00